Navigation Links
'Cipla, Tell the Truth'; AIDS Healthcare Foundation Launches New Ad Campaign
Date:9/6/2007

prices in India and to increase access to lifesaving medicines. As a non-profit organization with a twenty-year history of providing free medical care and advocacy to people living with HIV/AIDS our commitment has been, is, and always will be to the people we serve. We urge Cipla to end its attempts to divert attention away from the facts so that we can get down to the important work of saving lives."

AHF begins its open letter to Cipla by reiterating its original claim- which Cipla has yet to refute-that the generic manufacturer is offering many of its HIV/AIDS medicines at significantly lower prices in African than in India: "The simple truth is that Cipla is charging too much for its drugs in India and its pricing is depriving Indians living with HIV/AIDS of access to lifesaving treatment ... Cipla is charging much more for anti-retroviral (ARV) drugs in India than they do in Africa."

A chart included in the ad compares the private price Cipla offers in India to the government or non-governmental organization price offered in Africa and the private price offered in Uganda (where AHF operates free treatment clinics). The results are startling: Cipla offers Duovir-N, a combination of three generic anti-retroviral drugs, for two times as much in India as it does in Africa and almost one-and-a-half times as much than in Uganda. The price Cipla offers for Triomune, a combination of three generic anti-retroviral drugs, is three times as much in India as offered in Africa and two-and-a-half times as much as Cipla charges for the same drug in Uganda. Finally, the price Cipla offers for Efavir, a two-in-one anti-retroviral combination, is three times as much in India as offered in Africa or twice as much than Cipla charges in Uganda. Bottom line: All three of these potential lifesaving generic ARV combinations by Cipla are priced (or offered) at an average of two to three times less in Africa than they are priced (or offered) in India; as such, the steeper pr
'/>"/>

SOURCE AIDS Healthcare Foundation
Copyright©2007 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3 4 5 6 7

Related medicine news :

1. Healthcare sector is now a multi billion-dollar industry in India
2. Iodex goes to SmithKline Beecham consumer Healthcare
3. Healthcare Professionals Might Want To Rethink Their Dress Code
4. WHO report asks for improved healthcare for mother and child
5. New X-ray machine launched by GE Healthcare
6. India To March Ahead in The Global HealthCare Competition
7. Medical Fraternity Urged To Revamp Indian Healthcare
8. British Healthcare Mission Explores Partnership Possibilities With Indian Healthcare Sector
9. Need For Social Churning Emphasized In CMC Meet On ‘Leadership In Healthcare
10. LINK Applied Genomics Programme Promises To Revolutionize Healthcare Systems
11. India Can Manage World’s Healthcare Crisis By 202
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/4/2008)...RNewswire/ -- BAPTIST HEALTH, a six-hospital,syst...gest health system, has,expanded its use of Clini...,solution that enabled the system,s pharmacists to...ve more than $1 million. , "Data we collect...hat,CareFocus prompts approximately half of the p...
(Date:12/4/2008)...se seen with standard dose of daunorubicin, study ...ws) -- A high dose of the chemotherapy drug daunor...usly untreated acute myeloid leukemia (AML), preli...tional Cancer Institute (NCI) show. , AML is a ...cluded 633 patients, aged 16 to 60, who were rando...
(Date:12/4/2008)...s Leaders of Virginia, Maryland and D.C. AIDS Offi...wswire/ -- Nationally, Washington, D.C. ranks firs...C., 82 percent are African American. In an effort...the South, today,s Living Quilt roundtable at the ...e leaders of the Virginia, Maryland and District o...
(Date:12/4/2008)...his December, and on the eve of its 35th Anniversa...unch an integrated Season of Giving marketing camp... long way. The initiative, designed to drive perso...harity and its three core programs: Ronald McDonal...d McDonald Care Mobile. , ...
Breaking Medicine News(10 mins):Health News:BAPTIST HEALTH Uses Real-Time Clinical Surveillance from Thomson Reuters to Lower Costs and Improve Quality in the Pharmacy 2Health News:BAPTIST HEALTH Uses Real-Time Clinical Surveillance from Thomson Reuters to Lower Costs and Improve Quality in the Pharmacy 3Health News:Higher Chemo Drug Dose Prolongs Lives of Leukemia Patients 2Health News:Southern AIDS Living Quilt Raises Awareness in Washington, D.C. 2Health News:Southern AIDS Living Quilt Raises Awareness in Washington, D.C. 3Health News: Ronald McDonald House Charities Brings People Together Like Never Before with First-Ever, Multi-Channel Social Networking Campaign : Charity Finds New Ways to Encourage Seasonal Giving in Tough Economic Times 2Health News: Ronald McDonald House Charities Brings People Together Like Never Before with First-Ever, Multi-Channel Social Networking Campaign : Charity Finds New Ways to Encourage Seasonal Giving in Tough Economic Times 3
...gs from a recent study researchers say, the ancien...cal application. Lymphoma patients// who took part...n those in a control group. The study was conducte...ther undergoing treatment or who had concluded tre...
...extended exposure to sunlight may lead to age-rela...egeneration an eye // disorder that can cause blin...ts for five years and more than 2,700 patients for...86 years old. Participants who reported being in t...
...s( DVT ) is a blood clot that develops deep in the...lung. // People who require prolonged bed rest ar... blood circulation ,especially patients in intensi...a serious risk for DVT. Recent studies have shown ...
...w individuals in lower socioeconomic groups, as me...ul days than those with // higher socioeconomic st...rger impact on their health. While those with more...y are not as affected by it. For the study, more t...
Other Medicine News:
(Date:12/2/2008)...wire-FirstCall/ -- Biopure Corporation,(Nasdaq: ...l Research Center,(NMRC) has submitted to the Foo...gational new drug (IND) application to conduct a c... Hemopure(R) [hemoglobin glutamer - 250 (bovine)],...uma patients. The study is,entitled "Operation Re...
(Date:12/2/2008).../ -- Horizon Therapeutics, Inc., a,privately held...wo pivotal,Phase 3 trials evaluating its lead inv...primary endpoints. HZT-501, a novel, proprietary f...n and famotidine, demonstrated a,statistically si...dal,anti-inflammatory drug (NSAID)-induced upper ...
(Date:12/1/2008)...2 A study has found tha...ique for imaging the breast, is not affected by ei...two factors that limit the effectiveness of standa...s will be presented today at the annual meeting of... , , "The ability of PEM to detect cancer ...
(Date:12/1/2008)...- S*BIO Pte Ltd today announced the initiation of ... orally-active JAK2 inhibitor, in leading medical ...opathic myelofibrosis (CIMF). , , The tria...ity of SB1518 in patients with CIMF and is expecte... the study will assess the safety profile and eval...
Breaking Medicine Technology:U.S. Naval Medical Research Center Resubmits IND Application for Proposed 'Op RESUS' Clinical Trial in Trauma Patients in the Battlefield Setting 2U.S. Naval Medical Research Center Resubmits IND Application for Proposed 'Op RESUS' Clinical Trial in Trauma Patients in the Battlefield Setting 3Horizon Therapeutics Announces Two Pivotal HZT-501 Phase 3 Trials Meet Primary Endpoints 2Horizon Therapeutics Announces Two Pivotal HZT-501 Phase 3 Trials Meet Primary Endpoints 3Horizon Therapeutics Announces Two Pivotal HZT-501 Phase 3 Trials Meet Primary Endpoints 4New Mammography Technology Effective in Detecting Breast Cancer 2New Mammography Technology Effective in Detecting Breast Cancer 3New Mammography Technology Effective in Detecting Breast Cancer 4S*BIO Advances JAK2 Inhibitor SB1518 into Phase 1/2 Clinical Trial in Australia for the Treatment of Chronic Idiopathic Myelofibrosis 2S*BIO Advances JAK2 Inhibitor SB1518 into Phase 1/2 Clinical Trial in Australia for the Treatment of Chronic Idiopathic Myelofibrosis 3Minorities More Likely to Die in ER 27526 1Minorities More Likely to Die in ER 27526 2Minorities More Likely to Die in ER 27526 3Coleman Natural 28R 29 Foods Launches New and Improved Website 27523 1Coleman Natural 28R 29 Foods Launches New and Improved Website 27523 2Douglas Oberhelman Elected to Lilly Board of Directors 8390 1Douglas Oberhelman Elected to Lilly Board of Directors 8390 2Douglas Oberhelman Elected to Lilly Board of Directors 8390 3Sandia SES win Popular Mechanics Breakthrough Innovator Award 5467 1Sandia SES win Popular Mechanics Breakthrough Innovator Award 5467 2
...DGE, Mass.--(BUSINESS WIRE)--Mar 26, 2007 - Combin... preliminary results of,a phase 2 clinical trial s...prednisolone and the antidepressant paroxetine),an...oid arthritis,(RA). This trial served two importan...t of 3mg of prednisolone alone (a very low dose),i...
...Y, Mass.--(BUSINESS WIRE)--Mar 27, 2007 - Inotek,P...sentation of,positive Phase 2 clinical data demons...ntial for INO-1001 as a preventative agent for,car...n subjects,with acute ST-elevated myocardial infar...nary intervention. The presentation was,made in a ...
Other Medicine Technology:CombinatoRx Provides Topline Results from Phase 2 RA Study with,CRx-139 and Very Low Dose Prednisolone 2CombinatoRx Provides Topline Results from Phase 2 RA Study with,CRx-139 and Very Low Dose Prednisolone 3CombinatoRx Provides Topline Results from Phase 2 RA Study with,CRx-139 and Very Low Dose Prednisolone 4CombinatoRx Provides Topline Results from Phase 2 RA Study with,CRx-139 and Very Low Dose Prednisolone 5CombinatoRx Provides Topline Results from Phase 2 RA Study with,CRx-139 and Very Low Dose Prednisolone 6Inotek Pharmaceuticals Announces Presentation of Phase 2 Clinical,Data for INO-1001 at ACC Demonstrating PARP Inhibition and,Anti-inflammatory Activity in Plasma of Patients Undergoing Primary,Percutaneous Coronary Intervention 2Inotek Pharmaceuticals Announces Presentation of Phase 2 Clinical,Data for INO-1001 at ACC Demonstrating PARP Inhibition and,Anti-inflammatory Activity in Plasma of Patients Undergoing Primary,Percutaneous Coronary Intervention 3Inotek Pharmaceuticals Announces Presentation of Phase 2 Clinical,Data for INO-1001 at ACC Demonstrating PARP Inhibition and,Anti-inflammatory Activity in Plasma of Patients Undergoing Primary,Percutaneous Coronary Intervention 4
...X/See™ is a 1-step, hand-held, point-of-care...rug metabolites in human urine. The TOX/See devic...d drugs in 3 to 8 minutes and requires only a few ...lly packaged to maximize convenience and ease of u...
...X/See™ is a 1-step, hand-held, point-of-care...rug metabolites in human urine. The TOX/See devic...d drugs in 3 to 8 minutes and requires only a few ...lly packaged to maximize convenience and ease of u...
...X/See™ is a 1-step, hand-held, point-of-care...rug metabolites in human urine. The TOX/See devic...d drugs in 3 to 8 minutes and requires only a few ...lly packaged to maximize convenience and ease of u...
...X/See™ is a 1-step, hand-held, point-of-care...rug metabolites in human urine. The TOX/See devic...d drugs in 3 to 8 minutes and requires only a few ...lly packaged to maximize convenience and ease of u...
Medicine Products: